Centre Hospitalier Departemental Vendee
- Address
- lock Available on a paid plan
Centre Hospitalier Departemental Vendee - Comprehensive Cancer and Multi-Specialty Research Center
The Centre Hospitalier Departemental Vendee is a leading French medical research institution with extensive expertise in oncology and hematology clinical trials. The center demonstrates particular strength in investigating novel therapeutic approaches for multiple myeloma, with multiple Phase II and III studies evaluating innovative combinations including isatuximab, elranatamab, and bispecific antibodies in both newly diagnosed and relapsed/refractory disease settings. Their research portfolio spans the full spectrum of cancer care, from early-stage disease to advanced malignancies.
- Blood cancers including multiple myeloma, chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL)
- Solid tumor malignancies: lung cancer (NSCLC), colorectal cancer, breast cancer, and prostate cancer
- Chronic kidney disease and cardiovascular complications in renal disorders
- Critical care medicine including sepsis, ARDS, and cardiac arrest management
Beyond oncology, the center maintains an active research program in autoimmune conditions such as rheumatoid arthritis and giant cell arteritis, infectious diseases including prosthetic joint infections and catheter-related bloodstream infections, and complex metabolic disorders. The institution's participation in innovative therapeutic trials demonstrates commitment to precision medicine, particularly in targeted therapy optimization and immunotherapy combinations, while also addressing critical gaps in nephrology, transplant medicine, and emergency care protocols.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 25 therapeutic areas and 15 of 398 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 377 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 63 by active trials.
lock +62 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +36 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Departemental Vendee
lock Showing 1 of 209 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A double-blind randomized, Phase III study of radiotherapy combined with cetuXimab + Xevinapant compared to radiotherapy combined with cetuximab (Standard of care) + placebo in patients with Locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), unfit for high-dose cisplatin (XXL study) | Groupe Oncologie Radiotherapie Tete Cou | Phase III | Not Recruiting | Dec 2023 | Sep 2024 |
IMP list
lock Showing 1 of 398 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 15 | Unknown | 2017-12-14 | 2025-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.